Regenerex Pharma auditor resigns after 9 years

Regenerex Pharma’s long‑time auditor resigned effective August 31, 2026, as the company continues to face going‑concern disclosures and works to catch up on delayed SEC filings.

Accepted by SEC EDGAR 09/04/2026 - 04:48 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

REGENEREX PHARMA, INC. (RGPX) reports that its independent registered public accounting firm, dbbmckennon, resigned effective August 31, 2026, after serving in that role since 2017. The board acknowledged and accepted the firm’s internal decision to cease providing services.

dbbmckennon’s reports on the company’s financial statements for the fiscal years ended March 31, 2025 and December 31, 2025 contained no adverse or disclaimed opinions and were not qualified, but did include an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern, and for the April 1–December 31, 2025 transition period also noted a revision to disclose related party transactions. The company states there were no disagreements or reportable events with dbbmckennon under Regulation S‑K and is in the process of engaging a successor auditor while working to complete outstanding periodic reports and bring its SEC filings current.

Positive

• None.

Negative

• Auditor resignation: Long‑time independent auditor dbbmckennon resigned effective August 31, 2026, creating near‑term uncertainty around the audit function until a successor firm is engaged.
• Going‑concern uncertainty: Prior audit reports included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern.
• Delayed SEC reporting: The company discloses it is still working to complete outstanding periodic reports and to bring its SEC filings current.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Auditor resignation effective date: August 31, 2026 Fiscal year end: March 31, 2025 Fiscal year end: December 31, 2025 +2 more

5 metrics

Auditor resignation effective date August 31, 2026 Date dbbmckennon ceased serving as independent registered public accounting firm

Fiscal year end March 31, 2025 One of the two most recent fiscal years covered by dbbmckennon’s report

Fiscal year end December 31, 2025 Transition period end and audited year with going-concern explanatory paragraph

Auditor tenure start 2017 Year dbbmckennon began serving as the company’s independent registered public accounting firm

Transition period April 1, 2025 to December 31, 2025 Period for which the auditor noted a revision to disclose related party transactions

Key Terms

independent registered public accounting firm, going concern, reportable events, Emerging growth company, +1 more

5 terms

independent registered public accounting firm regulatory

"had been serving as the independent registered public accounting firm of Regenerex"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

going concern financial

"included an explanatory paragraph related to substantial doubt about the Company’s ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

reportable events regulatory

"there were no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K"

Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.

Emerging growth company regulatory

"Emerging growth company [X]"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

related party transactions financial

"contained an explanatory paragraph noting a revision made to the financial statements to disclose certain related party transactions"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change in auditor did RGPX disclose in this Form 8-K?

Regenerex Pharma, Inc. disclosed that dbbmckennon resigned as its independent registered public accounting firm, effective August 31, 2026, after serving in that role since 2017.

Did Regenerex Pharma (RGPX) report any disagreements with its former auditor?

No. The company states there were no disagreements with dbbmckennon on accounting principles, financial statement disclosure, or audit scope or procedures during the two most recent fiscal years.

What going-concern disclosure affects Regenerex Pharma (RGPX)?

Audit reports for the fiscal years ended March 31, 2025 and December 31, 2025 included an explanatory paragraph raising substantial doubt about Regenerex Pharma’s ability to continue as a going concern.

Were there any reportable events under Regulation S-K for RGPX?

The company reports that during its two most recent fiscal years there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S‑K in relation to dbbmckennon.

Is Regenerex Pharma (RGPX) current with its SEC filings?

No. Regenerex Pharma states it is continuing efforts to complete its outstanding periodic reports and to bring its SEC filings current, working with its future successor auditor.

How did RGPX’s auditor address related party transactions?

The audit report for the transition period from April 1, 2025 to December 31, 2025 included an explanatory paragraph noting a revision to the financial statements to disclose certain related party transactions.

Has Regenerex Pharma (RGPX) chosen a new auditor yet?

Not yet. The company states it is in the process of engaging a successor independent registered public accounting firm and intends to complete the engagement as promptly as practicable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001357878 false 0001357878 2026-09-04 2026-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2026

REGENEREX PHARMA, INC 

(Exact Name of Registrant as Specified in its Charter)

Nevada		000-53230		98-0479983
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5348 Vegas Drive #177 Las Vegas, NV		89108
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 761-7479

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] 

Item 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

(a) Resignation of Independent Registered Public Accounting Firm

On August 31, 2026, dbbmckennon (“dbbmckennon”), which had been serving as the independent registered public accounting firm of Regenerex Pharma, Inc. (the “Company”), notified the Company that, effective August 31, 2026, it had made the internal decision to cease providing services to the Company as its independent registered public accounting firm.

dbbmckennon had served as the Company's independent registered public accounting firm since 2017.

The Company's Board of Directors has acknowledged and accepted dbbmckennon's decision to cease providing services. 

The reports of dbbmckennon on the Company's financial statements for the fiscal years ended December 31, 2025 and March 31, 2025, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope except as follows.   The reports included an explanatory paragraph related to substantial doubt about the Company’s ability to continue as a going concern. In addition, the report  for the transition period from April 1, 2025 to December 31, 2025 contained an explanatory paragraph noting a revision made to the financial statements to disclose certain related party transactions.  

During the Company's two most recent fiscal years ended December 31, 2025 and March 31, 2025, there were no disagreements, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, with dbbmckennon on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of dbbmckennon, would have caused dbbmckennon to make reference to the subject matter of the disagreement in connection with its reports on the Company's financial statements.

During the Company's two most recent fiscal years ended December 31, 2025 and March 31, 2025, there were no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto, 

 The Company is currently in the process of engaging a successor independent registered public accounting firm. The Company intends to complete the engagement process as promptly as practicable and will cooperate with both dbbmckennon and the successor independent registered public accounting firm to facilitate an orderly transition.

Pursuant to item 304(a)(3) of Regulation S-K prior to this filing the Company provided dbbmckennon with a copy of its disclosures contained in this current report on Form 8-K and requested that dbbmckennon furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above disclosures. The Company intends to file such letter as Exhibit 16.1 to this Current Report on Form 8-K.

The Company is continuing its efforts to complete its outstanding periodic reports and bring its filings current. The Company intends to work closely with its successor independent registered public accounting firm to complete the Company's outstanding financial reporting obligations.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit	Description
16.1	Letter from dbbmckennon regarding change in certifying accountant
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Contact: Regenerex Pharma, Inc. 

Company Ph: 877-761-RGPX (7479)

Investor Relations Ph: (305) 927-5191

Email: investors@regenerexpharmainc.com 

regenerexpharma.com 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	REGENEREX PHARMA, INC.
	By:	/s/ Greg Pilant
Date: Sept 4, 2026	Name:	Greg Pilant
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-16.1 LETTER FROM DBBMCKENNON REGARDING CHANGE IN CERTIFYING ACCOUNTANT 2.2 KB
• EX-101 SCHEMA DOCUMENT 3.0 KB
• EX-101 LABELS LINKBASE DOCUMENT 13.8 KB
• EX-101 PRESENTATION LINKBASE DOCUMENT 9.7 KB